Dopaminergic modulation of social reward anticipation in depression: neural effects of amisulpride versus placebo

Abstract Reward processing deficits are a well-established mechanism underlying anhedonia, a core symptom of Major Depressive Disorder (MDD). Given the role of dopamine in mesocorticolimbic reward pathways, this study examined whether a single low dose of amisulpride (100 mg), which is thought to enhance dopaminergic transmission through presynaptic D 2/3 autoreceptor blockade, modulates brain activation during the anticipation of social rewards. A total of 58 participants with MDD and 57 healthy controls (HCs) participated in a double-blind, placebo-controlled, randomized trial. They received either amisulpride or placebo before completing a Social Incentive Delay task during functional magnetic resonance imaging (fMRI). Neural activation was examined in the ventral and dorsal striatum, pallidum, ventral tegmental area (VTA), anterior insula, and ventromedial prefrontal cortex. Anhedonia was assessed using self-report measures. Behaviorally, participants responded faster to reward than no-reward cues, with no significant differences between groups (MDD vs. HCs) or treatment conditions (amisulpride vs. placebo). On a neural level, amisulpride enhanced VTA activation during the anticipation of social rewards compared to no-reward cues. Relative to HCs, participants with MDD showed reduced right putamen activity when anticipating highly rewarding cues, which was not significantly affected by amisulpride. Within the MDD-amisulpride group, exploratory analyses revealed positive associations between anhedonia severity and activity in the putamen, VTA, and anterior insula, and higher striatal activity correlated with faster responses to highly rewarding cues. These findings suggest that while amisulpride enhances VTA activity during the anticipation of social rewards, core striatal deficits in MDD remain, underscoring both the potential and limitations of dopaminergic modulation in addressing social anhedonia.

Authors

Institutions

Publication Details

Journal
Neuropsychopharmacology
Published
2026-08-14
DOI
https://doi.org/10.1038/s41386-026-02521-z
Primary Topic
Neurotransmitter Receptor Influence on Behavior
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dopaminergic modulation of social reward anticipation in depression: neural effects of amisulpride versus placebo

Gerd Luippold, David Weigner, Moritz Hempel, Margot Popp et al.
Neuropsychopharmacology
Neurotransmitter Receptor Influence on Behavior
article

Dopaminergic modulation of social reward anticipation in depression: neural effects of amisulpride versus placebo

Gerd Luippold, David Weigner, Moritz Hempel, Margot Popp, Matti Gärtner, Christian Keicher, Simone Grimm, Rebecca Gruzman, Luisa Carstens, Christian F. Beckmann, Marvin Sören Meiering, Andreas Wunder, Sigurd D. Süßmuth, Maarten Mennes, Clara Walters
article en

Abstract

Abstract Reward processing deficits are a well-established mechanism underlying anhedonia, a core symptom of Major Depressive Disorder (MDD). Given the role of dopamine in mesocorticolimbic reward pathways, this study examined whether a single low dose of amisulpride (100 mg), which is thought to enhance dopaminergic transmission through presynaptic D 2/3 autoreceptor blockade, modulates brain activation during the anticipation of social rewards. A total of 58 participants with MDD and 57 healthy controls (HCs) participated in a double-blind, placebo-controlled, randomized trial. They received either amisulpride or placebo before completing a Social Incentive Delay task during functional magnetic resonance imaging (fMRI). Neural activation was examined in the ventral and dorsal striatum, pallidum, ventral tegmental area (VTA), anterior insula, and ventromedial prefrontal cortex. Anhedonia was assessed using self-report measures. Behaviorally, participants responded faster to reward than no-reward cues, with no significant differences between groups (MDD vs. HCs) or treatment conditions (amisulpride vs. placebo). On a neural level, amisulpride enhanced VTA activation during the anticipation of social rewards compared to no-reward cues. Relative to HCs, participants with MDD showed reduced right putamen activity when anticipating highly rewarding cues, which was not significantly affected by amisulpride. Within the MDD-amisulpride group, exploratory analyses revealed positive associations between anhedonia severity and activity in the putamen, VTA, and anterior insula, and higher striatal activity correlated with faster responses to highly rewarding cues. These findings suggest that while amisulpride enhances VTA activity during the anticipation of social rewards, core striatal deficits in MDD remain, underscoring both the potential and limitations of dopaminergic modulation in addressing social anhedonia.

Neuropsychopharmacology
Boehringer Ingelheim (Germany) (DE), Radboud University Nijmegen (NL), Radboud University Medical Center (NL), University of Oxford (GB), MSB Medical School Berlin (DE), Wellcome Centre for Integrative Neuroimaging (GB), Technical University of Applied Sciences Lübeck (DE), Littlemore Hospital (GB), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE), University of Lübeck (DE)
Boehringer Ingelheim, Bladder Cancer Advocacy Network
Reduced inequalities
Openalex Percentile: Top 15%
Neurotransmitter Receptor Influence on Behavior
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.